Citius Oncology, Inc. (NASDAQ:CTOR) Sees Large Drop in Short Interest

Citius Oncology, Inc. (NASDAQ:CTOR) saw a large drop in short interest in February. As of February 13th, there was short interest totaling 913,552 shares, a drop of 24.7% from the January 29th total of 1,213,142 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 183,334 shares, the short-interest ratio is currently 5.0 days. Based on an average daily volume of 183,334 shares, the short-interest ratio is currently 5.0 days. Currently, 1.1% of the shares of the company are sold short.

Institutional Investors Weigh In On Citius Oncology

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC purchased a new position in shares of Citius Oncology in the third quarter valued at approximately $15,582,000. Jane Street Group LLC purchased a new position in shares of Citius Oncology during the 2nd quarter worth $465,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Citius Oncology during the fourth quarter valued at about $104,000. IFP Advisors Inc raised its position in Citius Oncology by 163.2% in the fourth quarter. IFP Advisors Inc now owns 87,424 shares of the company’s stock valued at $87,000 after purchasing an additional 54,209 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after acquiring an additional 52,875 shares during the period. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $6.00.

Citius Oncology Stock Performance

NASDAQ CTOR traded up $0.02 on Wednesday, reaching $1.08. 432,492 shares of the company’s stock traded hands, compared to its average volume of 201,934. Citius Oncology has a fifty-two week low of $0.55 and a fifty-two week high of $6.19. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.32 and a current ratio of 0.83. The firm has a market cap of $95.21 million, a price-to-earnings ratio of -3.48 and a beta of 3.03. The stock has a 50 day moving average price of $1.11 and a 200-day moving average price of $1.43.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings data on Friday, February 13th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $3.94 million for the quarter, compared to analysts’ expectations of $4.37 million.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.